North Carolina pharmaceutical company BioDelivery Sciences International has extended its patent in Canada by 10 years, giving additional protection for the company’s core drug delivery technology.
Raleigh, North Carolina based BDSI’s (NASDAQ:BDSI) drug delivery technology releases medicine to a patient via a small piece of dissolvable film placed on the inside of the cheek. BDSI said Monday that Canada’s Office of Patented Medicines extended this BioErodible MucoAdhesive (BEMA) drug delivery technology patent from 2017 to 2027. The BEMA technology is used in BDSI’s first product, Onsolis, which quickly delivers the pain-killing drug fentanyl to cancer patients experiencing breakthrough pain.
The drug delivery system is also the basis for BEMA buprenorphine, which is currently in phase 3 clinical trials as a treatment for moderate to severe chronic pain. The technology is also used for BEMA buprenorphine/naloxene, a potential treatment for opioid dependence. The patent in Canada provides BDSI additional patent protection for Onsolis as well as the BEMA products still in development.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Onsolis was approved by the U.S. Food and Drug Administration in 2009; Health Canada approved the product last year. The product was originally scheduled to launch in Canada in the third quarter of 2010, but BDSI’s contract manufacturer encountered regulatory issues that temporarily halted Onsolis production. BDSI now expects to launch Onsolis in Canada in late March or early April.
Related articles
- BioDelivery Sciences disputes patent infringement claim (medcitynews.com)
